2023 ESMO临床实践指南:胰腺癌的诊断、治疗和随访

2023-09-05 欧洲肿瘤内科学会 Ann Oncol 发表于上海

指南主要内容涵盖了胰腺癌的诊断、分期,风险评估、治疗、疾病监测和随访。所有建议均基于现有的科学数据和集体专家意见。

中文标题:

2023 ESMO临床实践指南:胰腺癌的诊断、治疗和随访

英文标题:

Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

发布机构:

欧洲肿瘤内科学会

发布日期:

2023-09-05

简要介绍:

该指南涵盖诊断、分期、风险评估、治疗、疾病监测和随访。

多学科专家作者团队来自欧洲、亚洲和美国的不同机构和国家。

建议基于现有的科学数据和作者的集体专家意见。

ESMO-MCBS 和 ESCAT 评分为治疗选择(包括靶向治疗)提供了不同程度的证据。

在临床实践中,提供的所有建议都需要与患者以共同决策的方式进行讨论。

相关资料下载:
[AttachmentFileName(sort=1, fileName=2023 ESMO临床实践指南:胰腺癌的诊断、治疗和随访.pdf)] GetToolGuiderByIdResponse(projectId=1, id=240451c003331954, title=2023 ESMO临床实践指南:胰腺癌的诊断、治疗和随访, enTitle=Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up, guiderFrom= Ann Oncol, authorId=0, author=, summary=指南主要内容涵盖了胰腺癌的诊断、分期,风险评估、治疗、疾病监测和随访。所有建议均基于现有的科学数据和集体专家意见。 , cover=https://img.medsci.cn/Random/busy-reception-in-a-hospital-with-doctors-and-PUPDEB8.jpg, journalId=0, articlesId=null, associationId=14, associationName=欧洲肿瘤内科学会, associationIntro=欧洲肿瘤内科学会(ESMO,European Society for Medical Oncology )是1975年成立的非盈利组织,是欧洲领先的专业组织,致力于提高肿瘤内科的专业性,推进癌症治疗和护理的多学科诊疗方法。, copyright=0, guiderPublishedTime=Tue Sep 05 00:00:00 CST 2023, originalUrl=, linkOutUrl=, content=<p class="ce-list--remove-bullets__list-item__text">该指南涵盖诊断、分期、风险评估、治疗、疾病监测和随访。</p> <p class="ce-list--remove-bullets__list-item__text">多学科专家作者团队来自欧洲、亚洲和美国的不同机构和国家。</p> <p class="ce-list--remove-bullets__list-item__text">建议基于现有的科学数据和作者的集体专家意见。</p> <p class="ce-list--remove-bullets__list-item__text">ESMO-MCBS 和 ESCAT 评分为治疗选择(包括靶向治疗)提供了不同程度的证据。</p> <p class="ce-list--remove-bullets__list-item__text">在临床实践中,提供的所有建议都需要与患者以共同决策的方式进行讨论。</p>, tagList=[TagDto(tagId=718, tagName=胰腺癌)], categoryList=[CategoryDto(categoryId=4, categoryName=消化, tenant=100), CategoryDto(categoryId=5, categoryName=肿瘤, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=718, articleKeyword=胰腺癌, articleKeywordNum=6, guiderKeywordId=718, guiderKeyword=胰腺癌, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=2, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=5837, appHits=142, showAppHits=0, pcHits=541, showPcHits=5695, likes=0, shares=27, comments=4, approvalStatus=1, publishedTime=Fri Sep 08 16:00:00 CST 2023, publishedTimeString=2023-09-05, pcVisible=1, appVisible=1, editorId=0, editor=dajiong, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=3, createdBy=null, createdName=dajiong, createdTime=Fri Sep 08 13:41:32 CST 2023, updatedBy=8538692, updatedName=梅斯话题小助手, updatedTime=Sat Jan 06 09:06:50 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=上海, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2023 ESMO临床实践指南:胰腺癌的诊断、治疗和随访.pdf)])
2023 ESMO临床实践指南:胰腺癌的诊断、治疗和随访.pdf
下载请点击:
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2163067, encodeId=789a216306e87, content=<a href='/topic/show?id=5dab10e018a4' target=_blank style='color:#2F92EE;'>#乳腺癌诊断#</a><a href='/topic/show?id=415f10e0196f' target=_blank style='color:#2F92EE;'>#乳腺癌分期#</a><a href='/topic/show?id=1cfb23e6157' target=_blank style='color:#2F92EE;'>#乳腺癌治疗#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=107018, encryptionId=5dab10e018a4, topicName=乳腺癌诊断), TopicDto(id=107019, encryptionId=415f10e0196f, topicName=乳腺癌分期), TopicDto(id=23761, encryptionId=1cfb23e6157, topicName=乳腺癌治疗)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Mon Oct 16 14:00:46 CST 2023, time=2023-10-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2161794, encodeId=1e632161e948e, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=570e6483876, createdName=苏日娜, createdTime=Mon Oct 09 19:19:31 CST 2023, time=2023-10-09, status=1, ipAttribution=内蒙古), GetPortalCommentsPageByObjectIdResponse(id=2156830, encodeId=f5d6215683054, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJibu7hwJqpmHiaJgLLmJmcwp0WDTxWI3vqPBO1Mloq21VBOPqziapyibYatvd2QWHWicolL1vbVZHgpRQ/132, createdBy=d16a2107341, createdName=JZ Yang, createdTime=Sat Sep 09 07:24:58 CST 2023, time=2023-09-09, status=1, ipAttribution=浙江省)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2163067, encodeId=789a216306e87, content=<a href='/topic/show?id=5dab10e018a4' target=_blank style='color:#2F92EE;'>#乳腺癌诊断#</a><a href='/topic/show?id=415f10e0196f' target=_blank style='color:#2F92EE;'>#乳腺癌分期#</a><a href='/topic/show?id=1cfb23e6157' target=_blank style='color:#2F92EE;'>#乳腺癌治疗#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=107018, encryptionId=5dab10e018a4, topicName=乳腺癌诊断), TopicDto(id=107019, encryptionId=415f10e0196f, topicName=乳腺癌分期), TopicDto(id=23761, encryptionId=1cfb23e6157, topicName=乳腺癌治疗)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Mon Oct 16 14:00:46 CST 2023, time=2023-10-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2161794, encodeId=1e632161e948e, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=570e6483876, createdName=苏日娜, createdTime=Mon Oct 09 19:19:31 CST 2023, time=2023-10-09, status=1, ipAttribution=内蒙古), GetPortalCommentsPageByObjectIdResponse(id=2156830, encodeId=f5d6215683054, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJibu7hwJqpmHiaJgLLmJmcwp0WDTxWI3vqPBO1Mloq21VBOPqziapyibYatvd2QWHWicolL1vbVZHgpRQ/132, createdBy=d16a2107341, createdName=JZ Yang, createdTime=Sat Sep 09 07:24:58 CST 2023, time=2023-09-09, status=1, ipAttribution=浙江省)]
    2023-10-09 苏日娜 来自内蒙古

    感谢分享

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2163067, encodeId=789a216306e87, content=<a href='/topic/show?id=5dab10e018a4' target=_blank style='color:#2F92EE;'>#乳腺癌诊断#</a><a href='/topic/show?id=415f10e0196f' target=_blank style='color:#2F92EE;'>#乳腺癌分期#</a><a href='/topic/show?id=1cfb23e6157' target=_blank style='color:#2F92EE;'>#乳腺癌治疗#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=107018, encryptionId=5dab10e018a4, topicName=乳腺癌诊断), TopicDto(id=107019, encryptionId=415f10e0196f, topicName=乳腺癌分期), TopicDto(id=23761, encryptionId=1cfb23e6157, topicName=乳腺癌治疗)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Mon Oct 16 14:00:46 CST 2023, time=2023-10-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2161794, encodeId=1e632161e948e, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=570e6483876, createdName=苏日娜, createdTime=Mon Oct 09 19:19:31 CST 2023, time=2023-10-09, status=1, ipAttribution=内蒙古), GetPortalCommentsPageByObjectIdResponse(id=2156830, encodeId=f5d6215683054, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJibu7hwJqpmHiaJgLLmJmcwp0WDTxWI3vqPBO1Mloq21VBOPqziapyibYatvd2QWHWicolL1vbVZHgpRQ/132, createdBy=d16a2107341, createdName=JZ Yang, createdTime=Sat Sep 09 07:24:58 CST 2023, time=2023-09-09, status=1, ipAttribution=浙江省)]
    2023-09-09 JZ Yang 来自浙江省

    感谢分享

    0

拓展阅读

Eur Radiol:术前肌少症与胰十二指肠切除术后胰腺癌患者总生存率差相关

术前CT评估的肌少症是影响胰十二指肠切除术后胰腺癌患者总生存期的不良预后因素。肌少症性肥胖和新发糖尿病可能是胰十二指肠切除术后胰腺癌患者总生存期较差的预测因素。

胰腺癌个性化医疗的现状和未来

文章介绍胰腺癌的分子特征及治疗进展,包括PARPi、MEK抑制剂、EGFR抑制剂等多种药物的研究,还提及靶向肿瘤微环境、免疫疗法等,强调个性化治疗的前景。

JCO:北京大学齐长松团队发现CAR-T细胞治疗胰腺癌,疾病控制率达70.8%

以评估CT041在既往治疗过的胰腺癌(PC)患者中的作用(CT041是一种嵌合抗原受体(CAR)修饰的T细胞疗法,特异性靶向实体瘤中的CLDN18.2)。

Nat Commun:中南大学金鑫/华中科技大学江科/唐露发现KRAS加速胰腺癌进展的新机制

该研究使用KPC小鼠模型来探索棕榈酰化对胰腺癌进展的影响。KRAS上调诱导ZDHHC20在胰腺癌患者中异常过表达,与胰腺癌患者的预后不良相关。

JCO:北京大学齐长松团队发现CAR-T细胞疗法让胰腺癌实体瘤患者获益

该研究报告了两项探索性临床试验的汇总分析结果,以评估CT041在既往治疗过的胰腺癌(PC)患者中的作用。

Genes & Diseases:Mo YY/Yang L/Peng WX教授团队揭示LINC00901促进胰腺癌发展

文章报道了长链非编码RNA(lncRNA) LINC00901在胰腺癌的发生、发展中起重要的促进作用,并受到m6A修饰调控。

2010ESMO临床实践指南:胰腺癌

欧洲肿瘤内科学会(ESMO,European Society for Medical Oncology) · 2010-05-01

胰腺癌诊疗规范(2011年版)

中华人民共和国卫生部(MINISTRY OF HEALTH OF THE PEOPLE`S REPUBLIC OF CHINA) · 2011-10-14

2012 胰腺癌经动脉灌注化疗指南(草案)

中华医学会放射学分会介入学组 · 2012-05-30

2012 ESMO临床实践指南:胰腺癌

欧洲肿瘤内科学会(ESMO,European Society for Medical Oncology) · 2012-06-01

2013 胰腺癌多学科综合治疗协作组专家共识

中华医学会肿瘤学分会 · 2013-05-01